Disease-A-Month
Volume 53, Issue 4 , Pages 223-226 , April 2007

Complications of Dopaminergic Therapy

References 

  1. Horstink MWIMN, Zijlmans JC Mm, Pasman JW, et al. Which risk factors predict the levodopa response in fluctuating Parkinson’s diseae. Ann Neurol. 1990;27:537–543
  2. Horstink MWIMN, Zijlmans JC Mm, Pasman JW, et al. Severity of Parkinson’s disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psyachiatry. 1990;53:224–226
  3. Poewe WH, Lees AJ, Stern GM. Low dose l-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology. 1986;36:1528–1530
  4. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord. 1999;14:725–730
  5. Poewe W, Granata R, Geser F. Pharmacologic treatment of Parkinson’s disease. Mov Disord. 2004;19:247–271
  6. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs. 1998;55:1–9
  7. Metman LV, Konitsiotos S, Chase TN. Pathophysiology of motor response complications in Parkinsnon’s disease: hypotheses on the why, where and what. Mov Disord. 2000;15:3–8
  8. Calon F, Rajput AH, Hornykewicz O, et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson’s disease. Neurobiol Dis. 2003;14(3):404–416

PII: S0011-5029(07)00045-4

doi: 10.1016/j.disamonth.2007.05.004

Disease-A-Month
Volume 53, Issue 4 , Pages 223-226 , April 2007

Article Tools